ArticleCancers2026

Real-World Safety and Early Effectiveness of First-Line Enfortumab Vedotin Plus Pembrolizumab with Routine Dexamethasone Premedication in Advanced Urothelial Carcinoma.

Takuto Hara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.